Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors (Q38096411)

28 August 2017

title

Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors (English)

1 reference

28 August 2017

Mariangela Figini

5

0 references

Delia Mezzanzanica

object named as

Delia Mezzanzanica

2

0 references

author name string

Alessandro Satta

1

1 reference

28 August 2017

Fabio Turatti

3

1 reference

28 August 2017

Silvana Canevari

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 April 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

527-539

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Therapeutic antibodies for autoimmunity and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Potent antibody therapeutics by design

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Introduction to current and future protein therapeutics: a protein engineering perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Marketed therapeutic antibodies compendium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Harnessing the immune response to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Immunotherapeutic perspective for bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Preliminary trial of specific targeting therapy against malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Blinatumomab: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Treating cancer with genetically engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Impact of chimeric immune receptor extracellular protein domains on T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Redirected cytotoxic effector function. Requirements for expression of chimeric single chain high affinity immunoglobulin e receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood trans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

Quantitative Estimation of the Hybridization of Rabbit Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.203

21 January 2018

Identifiers

DOI

10.2217/FON.12.203

1 reference

28 August 2017

1 reference